Harrow, Inc. Proceeds from Financing Revenue Received under Leases
Harrow, Inc. (HROW) reported Proceeds from Financing Revenue Received under Leases of $1.93 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromFinancingRevenueReceivedUnderLeases · last filed 2018-03-08
- Harrow, Inc. proceeds from financing revenue received under leases for the quarter ending 2016-12-31 was $0.00.
- Harrow, Inc. proceeds from financing revenue received under leases for fiscal 2016 was $1.93M.
| Period end | Proceeds from Financing Revenue Received under Leases 3 month | Proceeds from Financing Revenue Received under Leases 9 month | Proceeds from Financing Revenue Received under Leases 12 month |
|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $1.93M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $1.93M 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |